The Effectiveness and Safety of High-Dose Colistin: Prospective Cohort Study

Clinical Infectious Diseases

Volumn 63, Issue 12, 2016, Pages 1605-1612

  Benattar, Yael Dishon ^a,b   Omar, Muna ^c,d   Zusman, Oren ^c,d   Yahav, Dafna ^c,d   Zak Doron, Yael ^a,e   Altunin, Sergey ^e   Elbaz, Michal ^d   Daitch, Vered ^d   Granot, Michal ^b   Leibovici, Leonard ^c,d   Paul, Mical ^a,e  

^a Infectious Diseases Unit   (Israel)

^b UNIVERSITY OF HAIFA   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d RABIN MEDICAL CENTER   (Israel)

^e TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Acinetobacter; hospital acquired infection; Klebsiella; multidrug resistant gram negative bacteria; polymyxin

Indexed keywords

ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; COLISTIN;

AGED; ANTIBIOTIC RESISTANCE; COHORT ANALYSIS; DOSE RESPONSE; FEMALE; GRAM NEGATIVE INFECTION; HEALTH STATUS INDICATOR; HUMAN; MALE; MORTALITY; PROSPECTIVE STUDY;

AGED; ANTI-BACTERIAL AGENTS; CARBAPENEMS; COHORT STUDIES; COLISTIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HEALTH STATUS INDICATORS; HUMANS; MALE; MORTALITY; PROSPECTIVE STUDIES;

EID: 85018189621     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw684     Document Type: Article

References (23)

1. Couet W, Grégoire N, Marchand S, Mimoz O. Colistin pharmacokinetics: The fog is lifting. Clin Microbiol Infect 2012; 18:30-9.
2. Yahav D, Farbman L, Leibovici L, Paul M. Colistin: New lessons on an old antibiotic. Clin Microbiol Infect 2012; 18:18-29.
3. Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 2011; 55:3284-94.
4. Gregoire N, Mimoz O, Megarbane B, et al. New colistin population pharmacokinetic data in critically ill patients suggesting an alternative loading dose rationale. Antimicrob Agents Chemother 2014; 58:7324-30.
5. Plachouras D, Karvanen M, Friberg LE, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009; 53:3430-6.
6. Paul M, Bishara J, Levcovich A, et al. Effectiveness and safety of colistin: Prospective comparative cohort study. J Antimicrob Chemother 2010; 65:1019-27.
7. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: 19th informational supplement. Document M100-S19. Wayne, PA: CLSI.
8. Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 2008; 36:309-32.
9. Dickstein Y, Leibovici L, Yahav D, et al. Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant gram-negative infections (AIDA): A study protocol. BMJ Open 2016; 6:e009956.
10. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P; Acute Dialysis Quality Initiative Workgroup. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8:R204-12.
11. Quan H, Li B, Couris CM, et al. Practice of epidemiology updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 2011; 173:676-82.
12. Ferreira FL, Bota DP, Bross A, Melot C, Vincent JL. Serial evaluation of the SOFA score to predict outcome in critically ill patients. JAMA 2001; 286: 1754-8.
13. Pogue JM, Lee J, Marchaim D, et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis 2011; 53:879-84.
14. Falagas ME, Rafailidis PI, Ioannidou E, et al. Colistin therapy for microbiologically documented multidrug-resistant gram-negative bacterial infections: A retrospective cohort study of 258 patients. Int J Antimicrob Agents 2010; 35:194-9.
15. Gibson GA, Bauer SR, Neuner EA, Bass SN, Lam SW. Influence of colistin dose on global cure in patients with bacteremia due to carbapenem-resistant gram-negative bacilli. Antimicrob Agents Chemother 2016; 60:431-6.
16. Vicari G, Bauer SR, Neuner EA, Lam SW. Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant gram-negative bacteremia. Clin Infect Dis 2013; 56:398-404.
17. Elefritz JL, Bauer KA, Jones C, Mangino JE, Porter K, Murphy CV. Efficacy and safety of a colistin loading dose, high-dose maintenance regimen in critically ill patients with multidrug-resistant gram-negative pneumonia. J Intensive Care Med 2016:pii:0885066616646551.
18. Trifi A, Abdellatif S, Daly F, et al. Efficacy and toxicity of high-dose colistin in multidrug-resistant gram-negative bacilli infections: A comparative study of a matched series. Chemotherapy 2016; 61:190-6.
19. Eliopoulos GM, Schwaber MJ, Carmeli Y. An ongoing national intervention to contain the spread of carbapenem-resistant Enterobacteriaceae. Clin Infect Dis 2014; 58:697-703.
20. Schwaber MJ, Lev B, Israeli A, et al. Containment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clin Infect Dis 2011; 52:848-55.
21. Kristoffersson A, Friberg L, eds. Design and interim evaluation of a sparse sampling schedule for estimation of individual colistin pharmacokinetics [abstract I-66]. In: Abstracts of the Annual Meeting of the Population Approach Group in Europe, Lisbon, Portugal, 2016:5962.
22. DeRyke CA, Crawford AJ, Uddin N,Wallace MR. Colistin dosing and nephrotoxicity in a large community teaching hospital. Antimicrob Agents Chemother 2010; 54:4503-5.
23. Tuon FF, Rigatto MH, Lopes CK, Kamei LCK, Rocha JL, Zavascki AP. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Agents 2014; 43:349-52.